Literature DB >> 21732826

Letter written in response to van bon et Al.: "Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial".

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21732826      PMCID： PMC3136718          DOI： 10.1089/dia.2011.0122

Source DB:  PubMed          Journal:  Diabetes Technol Ther        ISSN： 1520-9156            Impact factor:   6.118


× No keyword cloud information.
  2 in total

1.  Safety of insulin glulisine when given by continuous subcutaneous infusion using an external pump in patients with type 1 diabetes.

Authors:  R P Hoogma; D Schumicki
Journal:  Horm Metab Res       Date:  2006-06       Impact factor: 2.936

2.  Insulin glulisine compared to insulin aspart and to insulin lispro administered by continuous subcutaneous insulin infusion in patients with type 1 diabetes: a randomized controlled trial.

Authors:  Arianne C van Bon; Bruce W Bode; Caroline Sert-Langeron; J Hans DeVries; Guillaume Charpentier
Journal:  Diabetes Technol Ther       Date:  2011-04-02       Impact factor: 6.118
  2 in total
  1 in total

Review 1.  Continuous subcutaneous insulin infusion in diabetes: patient populations, safety, efficacy, and pharmacoeconomics.

Authors:  Paolo Pozzilli; Tadej Battelino; Thomas Danne; Roman Hovorka; Przemyslawa Jarosz-Chobot; Eric Renard
Journal:  Diabetes Metab Res Rev       Date:  2015-06-22       Impact factor: 4.876
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.